Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | GPR183 | P32249 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29957433 | 1.00 | ENPP2 (0.46) | ENPP2MEN1KMT2AMLYCDNLRP3 | |
| SCHEMBL15281239 | 0.84 | KMT2A (0.50) | MEN1KMT2AMLYCDTRPM8LMNA | |
| SCHEMBL29902315 | 0.83 | ERN1 (0.48) | ENPP2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL177412 | 0.83 | ERN1 (0.48) | ENPP2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL29729945 | 0.80 | CES2 (0.53) | MEN1KMT2AMLYCDKDM4EALDH1A1 | |
| SCHEMBL305837 | 0.80 | CES2 (0.53) | MEN1KMT2AMLYCDKDM4EALDH1A1 | |
| SCHEMBL130927 | 0.80 | MLYCD (0.53) | ENPP2MLYCDKDM4EALDH1A1HPGD | |
| SCHEMBL16214051 | 0.80 | MEN1 (0.46) | MEN1KMT2AMLYCDALDH1A1HPGD | |
| SCHEMBL32424912 | 0.78 | HPGD (0.57) | MEN1KMT2AMLYCDHPGDHSD17B2 | |
| SCHEMBL2652369 | 0.78 | HPGD (0.57) | MEN1KMT2AMLYCDHPGDHSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144767-A1 | TARGETED NITROXIDE AGENTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-05-11 | — | — | US | disclosed |
| US-20210371460-A1 | TARGETED NITROXIDE AGENTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-12-02 | — | — | US | disclosed |
| US-10751273-B2 | Compounds for the treatment of pathologies associated with aging and degenerative disorders | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190210969-A1 | INTRAESOPHAGEAL ADMINISTRATION OF TARGETED NITROXIDE AGENTS FOR PROTECTION AGAINST IONIZING IRRADIATION-INDUCED ESOPHAGITIS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-07-11 | — | — | US | disclosed |
| US-20180298054-A1 | TARGETED NITROXIDE AGENTS | University of Pittsburgh - of the Commonwealth Sys tem of Higher Education (US) | 2018-10-18 | — | — | US | disclosed |
| US-9890192-B2 | Targeted nitroxide agents | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2018-02-13 | — | — | US | disclosed |
| US-9732105-B2 | Targeted nitroxide agents | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160151269-A1 | COMPOUNDS FOR THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH AGING AND DEGENERATIVE DISORDERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-06-02 | — | — | US | disclosed |
| US-20160137692-A1 | TARGETED NITROXIDE AGENTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-05-19 | — | — | US | disclosed |
| US-20160068556-A1 | TARGETED NITROXIDE AGENTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-03-10 | — | — | US | disclosed |
| US-8324204-B2 | Fused thiophene derivatives as kinase inhibitors | UCB PHARMA SA (BE) | 2012-12-04 | — | — | US | disclosed |
| US-8288551-B2 | Targeted nitroxide agents | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120252733-A1 | USE OF TARGETED NITROXIDE AGENTS IN BONE HEALING | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120207687-A1 | TOPICAL FORMULATIONS OF TARGETED NITROXIDE AGENTS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2012-08-16 | — | — | US | disclosed |
| US-20120004263-A1 | Compounds for the treatment of pathologies associated with aging and degenerative disorders | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-01-05 | — | — | US | disclosed |
| US-20110172214-A1 | USE OF TARGETED NITROXIDE AGENTS IN PREVENTING, MITIGATING AND TREATING RADIATION INJURY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2011-07-14 | — | — | US | disclosed |
| WO-2010141824-A2 | USE OF TARGETED NITROXIDE AGENTS IN BONE HEALING | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-12-09 | — | — | WO | disclosed |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100035869-A1 | TARGETED NITROXIDE AGENTS | PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, UNIVERSITY OF | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172214-A1 | USE OF TARGETED NITROXIDE AGENTS IN PREVENTING, MITIGATING AND TREATING RADIATION INJURY | TXNRD2, TXN2, HSPE1 | ENPP2 2379/4885MEN1 3690/4885KMT2A 3662/4885 |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | ENPP2 1363/4885MEN1 859/4885KMT2A 4408/4885 |
| US-20190210969-A1 | INTRAESOPHAGEAL ADMINISTRATION OF TARGETED NITROXIDE AGENTS FOR PROTECTION AGAINST IONIZING IRRADIATION-INDUCED ESOPHAGITIS | HSPE1, HSPA9, HSPD1 | ENPP2 1651/4885MEN1 2497/4885KMT2A 4317/4885 |
| US-20160151269-A1 | COMPOUNDS FOR THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH AGING AND DEGENERATIVE DISORDERS | GLA, AGER, SIRT1 | ENPP2 662/4885MEN1 3812/4885KMT2A 3286/4885 |
| US-20120207687-A1 | TOPICAL FORMULATIONS OF TARGETED NITROXIDE AGENTS | NOX1, OGG1, NOX5 | ENPP2 1905/4885MEN1 4054/4885KMT2A 2809/4885 |
| US-20160137692-A1 | TARGETED NITROXIDE AGENTS | TXNRD2, TXN2, HSPE1 | ENPP2 2178/4885MEN1 3895/4885KMT2A 3194/4885 |
| US-20120004263-A1 | Compounds for the treatment of pathologies associated with aging and degenerative disorders | GLA, AGER, SIRT1 | ENPP2 662/4885MEN1 3812/4885KMT2A 3286/4885 |
| US-20180298054-A1 | TARGETED NITROXIDE AGENTS | TXNRD2, TXN2, HSPE1 | ENPP2 2178/4885MEN1 3895/4885KMT2A 3194/4885 |
| US-20100035869-A1 | TARGETED NITROXIDE AGENTS | TXNRD2, TXN2, HSPE1 | ENPP2 2178/4885MEN1 3895/4885KMT2A 3194/4885 |
| US-10751273-B2 | Compounds for the treatment of pathologies associated with aging and degenerative disorders | GLA, AGER, SIRT1 | ENPP2 662/4885MEN1 3812/4885KMT2A 3286/4885 |
| US-20120252733-A1 | USE OF TARGETED NITROXIDE AGENTS IN BONE HEALING | NME4, TFAM, COX5B | ENPP2 922/4885MEN1 4693/4885KMT2A 4433/4885 |
| US-20230144767-A1 | TARGETED NITROXIDE AGENTS | TXNRD2, TXN2, HSPE1 | ENPP2 2178/4885MEN1 3895/4885KMT2A 3194/4885 |
| US-20210371460-A1 | TARGETED NITROXIDE AGENTS | TXNRD2, TXN2, HSPE1 | ENPP2 2178/4885MEN1 3895/4885KMT2A 3194/4885 |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | PIKFYVE, PI4KA, PIK3CA | ENPP2 1278/4885MEN1 2762/4885KMT2A 2175/4885 |
| US-20160068556-A1 | TARGETED NITROXIDE AGENTS | NOXO1, NOX1, TPX2 | ENPP2 583/4885MEN1 3838/4885KMT2A 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.